Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers;...
October 27, 2025 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...
October 16, 2025 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...
September 25, 2025 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...
August 11, 2025 16:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in...
August 05, 2025 07:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers;...
July 31, 2025 07:45 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable...
July 08, 2025 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different...
May 16, 2025 16:35 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
May 06, 2025 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and...